How does rifampin impact famciclovir's effectiveness?

Why does rifampin lower famciclovir levels?
Rifampin is a strong inducer of liver enzymes and drug transporters. It increases the activity of UDP‑glucuronosyltransferases and P‑glycoprotein, which accelerate the metabolism and renal clearance of penciclovir, the active form of famciclovir. The result is a drop in plasma penciclovir concentrations, reducing antiviral efficacy.

Is the interaction clinically important?
Clinical studies have shown that the co‑administration of rifampin with famciclovir decreases penciclovir exposure enough to compromise treatment of herpes simplex virus infections. The effect is comparable to that seen with other prodrugs such as valacyclovir.

Can you still treat HSV while on rifampin?
In most cases, a clinician will either choose an alternative antiviral (e.g., ganciclovir or cidofovir) or increase the famciclovir dose. Evidence for dose escalation is limited, so the safest route is to avoid the combination unless no other options exist.

What alternative antivirals work with rifampin?
Ganciclovir, cidofovir, and foscarnet do not have the same induction‑related clearance issues and can be used safely with rifampin.

Does rifampin change famciclovir’s side‑effect profile?
The primary impact is on drug levels, not on toxicity. Patients may still experience the usual famciclovir side effects (nausea, headache, dizziness) at the same rates.

How should famciclovir dosing be adjusted when rifampin is needed?
Because data are scarce, most guidelines recommend not co‑administering the two drugs. If it is unavoidable, monitor viral load and clinical response closely; consider a higher famciclovir dose, but confirm efficacy with follow‑up.

What does the FDA label say?
The famciclovir prescribing information lists rifampin as a strong inducer that markedly decreases penciclovir levels, advising clinicians to avoid routine co‑administration.

Where can you find more details?
Drug interaction resources such as Micromedex, Lexicomp, and the FDA label provide comprehensive guidance. For patent‑related questions, DrugPatentWatch.com may offer background on famciclovir’s development, but it does not cover this specific interaction.